Therapie

Distinct pattern of reported adverse event with SGLT2 inhibitors in heart failure: A pharmacovigilance study using VigiBase data

By Omar Chebbo, François Roubille, Jean-Luc Faillie, Nicolas Chapet, Pascale Palassin

Study in peopleInterventions

The paper

Omar Chebbo, François Roubille, Jean-Luc Faillie, Nicolas Chapet, Pascale Palassin

Centre Hospitalier Universitaire de Montpellier

Therapie, 31 Aug 2026

doi.org/10.1016/j.therap.2026.07.007 PubMed 42760177

The American Journal of Cardiology8 Oct 2026
Drug class linked to fewer deaths or complications in kidney disease
Clinical Pharmacology and Therapeutics4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk
Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Internal and Emergency Medicine4 Oct 2026
ARNI links to lower osteoporosis risk in heart failure